HER2-positive metastatic breast cancer (MBC) and early breast cancer (EBC) research hub

APRILIAH (Aprogen Phase III Clinical Trial to Compare Efficacy, Safety, and Immunogenicity of AP063 in Subjects with HER2+ Breast Cancer)

This study, called APRILIAH, is looking at a new medicine for women with HER2-positive breast cancer. It's comparing this new treatment to existing ones to see if it's safe and works well for both advanced and early stages of the disease.